AstraZeneca is to raise $3.5 billion to fund a global development and marketing collaboration with Daiichi Sankyo, for an antibody-drug conjugate and potential new targeted cancer medicine,
Almirall has signed a new research collaboration with Chinese biotech HitGen, to find potential new oral therapies for moderate to severe atopic dermatitis – otherwise known as eczema.
The dwindling number of amyloid-targeting drugs in development for Alzheimer’s disease (AD) has been reduced by one more, after Biogen and Eisai pulled the plug on aducanumab.
UK biotech is booming, with the number of R&D companies increasing 65% since 2016 amid soaring annual investment of more than £2 billion, according to a new report.
UK artificial intelligence (AI) drug discovery company Exscientia has agreed a three year drug discovery deal with Celgene, focusing on finding new cancer and autoimmune drugs.